截至2025年12月31日收盘，新华制药（000756）报收于15.41元，较上周的15.81元下跌2.53%。本周， 新华制药12月29日盘中最高价报15.85元。12月31日盘中最低价报15.4元。新华制药当前最新总市值 106.29亿元，在化学制药板块市值排名49/150，在两市A股市值排名1817/5181。 公司同时获得缬沙坦胶囊药品注册证书（国药准字H20256391），注册分类为化学药品4类，用于轻、 中度原发性高血压治疗，属医保甲类品种。2024年中国公立医疗机构该产品销售额约为18.2亿元。两项 获批有助于提升公司产品竞争力，但销售受政策与市场因素影响，存在不确定性。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 公司公告汇总：新华制药获间苯三酚注射液药品注册证书，拓展新市场。 公司公告汇总：缬沙坦胶囊获批，丰富心血管产品线。 公司公告汇总：间苯三酚注射液2024年公立医疗机构销售额约9亿元。 公司公告汇总：缬沙坦胶囊2024年公立医疗机构销售额约18.2亿元。 本周关注点 公司公告汇总 新华制药近日取得间苯三酚 ...

Group 1 - Nan Mining Group signed a procurement contract for iron ore equipment worth 3 billion yuan with Lanyan Weiye Mineral Processing Co., Ltd., for a project processing over 4.6 million tons of ore annually, with an estimated operational cost of 3 billion yuan over 10 years [1] - Guangdong Yuedian A's Dapu Power Plant Phase II Project's Unit 4 has commenced commercial operation, with a total investment of 8.122 billion yuan and an expected annual power generation of 9 billion kilowatt-hours [2] - China Energy Engineering's subsidiary won an EPC general contracting project in Shaanxi Province with a bid amount of approximately 6.864 billion yuan, covering ecological governance, infrastructure, urban renewal, and water conservancy projects, with a total construction period of 36 months [3] Group 2 - ST Dongtong's stock will resume trading on December 30, 2025, entering a delisting arrangement period of 15 trading days, with the last trading date expected to be January 21, 2026 [4] - Roman Co.'s subsidiary signed a contract for a computing power service project worth approximately 156 million yuan with Tianjin Maoyuan Equipment Leasing Co., Ltd. and China Merchants Intelligent Supply Chain Service Co., Ltd. [5] - Hangzhou Thermal Power plans to sign a three-year coal purchase contract with Shanghai Yitai Shenpu for a total of 9 million tons, ensuring stable coal supply from 2026 to 2028 [6] Group 3 - Caitong Securities received approval from the China Securities Regulatory Commission to publicly issue bonds totaling no more than 15 billion yuan [7] - Qipai Technology's application for a stock issuance to specific investors has been approved by the Shanghai Stock Exchange [8] - China Software plans to sell 555 units of X86 servers and two properties to optimize idle assets, with a total estimated value of approximately 6.758 million yuan [10] Group 4 - Xinhua Medical received medical device registration certificates for two products, including an interleukin-6 test kit and a dual test kit for procalcitonin/interleukin-6 [11] - Shandong Haohua announced the resignation of Deputy General Manager Yuan Falin due to personal reasons [12] - Haixiang Pharmaceutical's invested company NWRD06 injection has completed the enrollment of the first subject in its Phase II clinical trial [13] Group 5 - Tiantong Co. terminated the absorption merger of its wholly-owned subsidiary Tiantong Rijing Precision Technology Co., Ltd., retaining its independent legal status [14] - Ruima Precision's subsidiary received a project designation for automotive air suspension systems, with an estimated sales revenue of approximately 1.342 billion yuan over a six-year lifecycle [15] - Ningbo Huaxiang's subsidiary signed a strategic cooperation agreement with Qianxing Future to enhance collaboration in the development and manufacturing of quadruped robots [16] Group 6 - Huali Co. terminated the acquisition of a 51% stake in Zhongke Huilian due to failure to reach consensus on key transaction terms [17] - Acolyte's olefin copolymer has passed customer verification and is now in bulk supply for the optical lens sector [18] - Tianjian Technology signed a supplementary agreement for military product price adjustments, expecting a revenue reduction of approximately 256 million yuan [19] Group 7 - Southeast Network Framework won an EPC project bid for the "China Vision Valley Industrial Base" with a total bid amount of 888 million yuan [20] - Baodi Mining plans to acquire 87% of Congling Energy for a total of 685 million yuan through a combination of cash and share issuance [21] - Heng Rui Pharmaceutical received clinical trial approval for multiple drugs, including HRS-6257 tablets for treating acute and chronic pain [22] Group 8 - Zhongxin Saike received a dividend of 60 million yuan from its wholly-owned subsidiary [23] - ST Songfa's subsidiary signed a contract for the construction of an oil tanker with a total contract value of approximately 80 to 100 million USD [24] - China Resources Double Crane received clinical trial approval for hydroxocobalamin injection, aimed at treating metabolic disorders in children [25][26]

格隆汇12月29日丨新华制药(000756.SZ)公布，收到国家药品监督管理局核准签发的间苯三酚注射液 《药品注册证书》。本品用于治疗消化系统和胆道功能障碍引起的急性痉挛性疼痛；急性痉挛性尿道、 膀胱、肾绞痛；妇科痉挛性疼痛。 ...

人民财讯12月29日电，新华制药（000756）12月29日公告，公司近日收到国家药监局核准签发的缬沙坦 胶囊、间苯三酚注射液《药品注册证书》。缬沙坦胶囊用于治疗轻、中度原发性高血压。间苯三酚注射 液用于治疗消化系统和胆道功能障碍引起的急性痉挛性疼痛；急性痉挛性尿道、膀胱、肾绞痛；妇科痉 挛性疼痛。 ...

格隆汇12月29日丨山东新华制药股份(00719.HK)发布公告，近日，公司收到国家药品监督管理局核准签 发的间苯三酚注射液《药品注册证书》。本品用于治疗消化系统和胆道功能障碍引起的急性痉挛性疼 痛；急性痉挛性尿道、膀胱、肾绞痛；妇科痉挛性疼痛。 ...

山东新华制药（000756）股份(00719)发布公告，近日，山东新华制药股份有限公司(以下简称"新华制 药"或"本公司")收到国家药品监督管理局核准签发的间苯三酚注射液(以下简称"本品")《药品注册证 书》。 2024年7月，新华制药向国家药品监督管理局药品审评中心(CDE)递交间苯三酚注射液境内生产药品上 市许可注册申报资料并获受理，2025年12月获得《药品注册证书》，审评结论为：批准注册。 本品用于治疗消化系统和胆道功能障碍引起的急性痉挛性疼痛;急性痉挛性尿道、膀胱、肾绞痛;妇科痉 挛性疼痛。 本品属于《国家基本医疗保险、工伤保险和生育保险药品目录(2025年)》乙类品种。根据相关统计数 据，2024年中国公立医疗机构间苯三酚注射液销售额约为人民币9亿元。 ...

智通财经APP讯，山东新华制药股份(00719)发布公告，近日，山东新华制药股份有限公司(以下简称"新 华制药"或"本公司")收到国家药品监督管理局核准签发的间苯三酚注射液(以下简称"本品")《药品注册 证书》。 2024年7月，新华制药向国家药品监督管理局药品审评中心(CDE)递交间苯三酚注射液境内生产药品上 市许可注册申报资料并获受理，2025年12月获得《药品注册证书》，审评结论为：批准注册。 本品用于治疗消化系统和胆道功能障碍引起的急性痉挛性疼痛;急性痉挛性尿道、膀胱、肾绞痛;妇科痉 挛性疼痛。 本品属于《国家基本医疗保险、工伤保险和生育保险药品目录(2025年)》乙类品种。根据相关统计数 据，2024年中国公立医疗机构间苯三酚注射液销售额约为人民币9亿元。 ...

Core Points - The National Organization for Drug Procurement has canceled the procurement qualification of Ningbo Dahongying Pharmaceutical's fluorouracil injection due to quality issues, placing the company and its contract manufacturer on a violation list, prohibiting them from participating in national drug procurement from October 15, 2025, to April 14, 2027 [1][5] - This incident highlights ongoing quality control issues within the pharmaceutical industry, despite existing regulations and oversight mechanisms [2][8] - The cancellation of procurement qualifications serves as a warning to other companies about the importance of maintaining drug quality to avoid losing market share and damaging brand reputation [2][8] Industry Impact - The fluorouracil injection, a widely used chemotherapy drug, had a market size of approximately $30 million in the U.S. and about 550 million yuan in China in 2023 [4] - The competitive landscape for fluorouracil injection saw seven companies successfully bid in the tenth national procurement, with Ningbo Dahongying's bid price being 2.97 yuan for a 10ml:0.25g specification [4] - The cancellation of procurement qualifications for multiple products indicates a broader trend of quality issues affecting various pharmaceutical companies, including Jiangxi Jingrui and Shanxi Yanghe [5][6] Regulatory Environment - The regulatory framework for drug procurement has been evolving, with the upcoming eleventh batch of national drug procurement set to impose stricter quality control measures, including requiring companies to have at least two years of experience in producing similar formulations [8][9] - The emphasis on quality in the procurement process is expected to benefit companies with stable production processes and strict quality controls, potentially raising the overall quality standards in the industry [9][10] Strategic Recommendations - Companies are encouraged to balance quality and cost-effectiveness by optimizing production processes, increasing R&D investment, expanding market reach, and establishing stable supply chains [10] - Engaging in national drug procurement with a focus on quality assurance and reasonable pricing strategies can help companies gain market share and build patient trust [10]

Core Points - The National Organization for Drug Procurement Office has announced the cancellation of the selection qualification for Ningbo Dayang Pharmaceutical Co., Ltd. for its fluorouracil injection, placing both Ningbo Dayang and Heilongjiang Fuhe Pharmaceutical Group Co., Ltd. on a "violation list" and suspending their eligibility to participate in national drug procurement from October 15, 2025, to April 14, 2027 [2][3] Group 1: Company Actions and Penalties - Ningbo Dayang Pharmaceutical was penalized for producing substandard fluorouracil injection, leading to the confiscation of illegal products and fines as per the Zhejiang Provincial Drug Administration's administrative penalty [2] - The announcement indicates that the main supply provinces for fluorouracil injection, where Ningbo Dayang is the primary supplier, will initiate a replacement procedure with backup suppliers taking over the supply responsibilities [3] Group 2: Industry Context - Fluorouracil injection is an anti-cancer drug included in the tenth batch of national drug procurement, with a winning bid price of 2.97 yuan for a 10ml:0.25g vial, supplied to provinces including Beijing, Zhejiang, Anhui, Guizhou, and Xinjiang [3] - Since 2025, the National Organization for Drug Procurement Office has repeatedly canceled the selection qualifications of multiple pharmaceutical companies in the tenth batch of procurement, indicating a trend of strict enforcement of compliance and quality standards in the industry [4][5][6]

Core Viewpoint - The article highlights the cancellation of the procurement qualification of Ningbo Dayang Pharmaceutical Co., Ltd. for its fluorouracil injection due to violations of quality standards, emphasizing the increasing scrutiny on drug quality in the national centralized procurement process [2][4]. Group 1: Company Overview - Ningbo Dayang Pharmaceutical, founded in 1956, is a comprehensive pharmaceutical company involved in manufacturing, research, and sales, and is currently controlled by Haier Shijie Biomedical Co., Ltd. since 2013 [3]. - Fluorouracil is a widely used first-generation antimetabolite chemotherapy drug, applicable in treating various cancers, including gastrointestinal, gynecological, head and neck, lung, liver, and bladder cancers [3]. Group 2: Procurement and Regulatory Actions - The National Organization for Drug Procurement Office announced the cancellation of Dayang Pharmaceutical's qualification for fluorouracil injection, which was part of the tenth batch of national centralized procurement, due to the production of substandard drugs [2][4]. - Dayang Pharmaceutical's bid price for fluorouracil injection was 2.97 yuan per 10ml (0.25g), which was relatively high compared to other bidders, as there were seven companies that won the bid [3]. - Since the implementation of the tenth batch of national drug procurement, there has been a trend of increased regulatory scrutiny on the production quality of selected drugs, with four companies, including Dayang Pharmaceutical, being disqualified due to quality issues [4][5]. Group 3: Industry Implications - The article indicates that three out of the four disqualified companies are classified as pure B-license enterprises, which lack production capabilities and rely on contract manufacturing [5]. - The regulatory challenges posed by the increasing participation of pure B-license enterprises in the bidding process highlight the need for stricter quality oversight in the pharmaceutical industry [5].